rais pt growth
improv growth outlook warrant re-rat
rais pt reiter buy rate attend
last week investor day review model confid enough
improv growth outlook show acceler organ constant currenc
growth furthermor believ trend could
persist driven book backlog growth
segment new product offer market share gain technolog
analyt ta believ investor pay larg cap growth
stori market leadership big data high visibl
deliv vision im quintil combin merger
thesi met high level skeptic investor primari
oper goal set manag integr data
clinic trial process creat next gener cro differenti
capabl competit improv world evid rwe
offer combin best asset practic two busi
improv technolog platform introduc new product expand
new market three year later think manag met
exceed oper goal
deliv number time merger compani also set
financi goal improv revenu growth basi point
achiev eventu mil cost synergi buy back bil
stock drive doubl digit adjust ep growth use midpoint
guidanc endpoint compani met exceed financi
rais bar investor day june compani
rais year revenue compound-annual-growth-rate target
furthermor expect three divis show revenu
growth acceler high singl digit organ ta
csm manag also identifi anoth mil run-rat cost save
exit end result would ebitda compound-annual-growth-rate
vs compound-annual-growth-rate continu buy back
expect compani drive solid doubl digit adjust ep
total sum part believ investor ascrib higher
multipl larg cap compani acceler growth high visibl
strong free cash flow typic pe rang stock
expect y/i growth
expect y/i growth
tr target
revenu depict prior year
adjust account rule
revenu prior reflect account
line cro peer group compani demonstr faster growth ta industri lead
growth think investor begin compar mid/larg cap high visibl
growth compani typic trade pe low- mid- see comp tabl
therefor rais pt assum pe appli estim
page
page
epstickerindustryemployeespricemktcapshar cashdebtevgrowthgrowthepsepsmid-cap technolog servicesadpdata process product commerci process technolog process process commerci health factset strh share upsid current strh scenariovaluationstrh model ia hold inc
page
sandi draper statement dollar y/i total gross depreci restructur merger impair oper fit incl restruc net interest expens incom incom incom tax tax equiti unconsolid equiti earn unconsolid net net loss incom attribut non-controlling net incom attribut dilut dilut share forma adjust net adj pre-tax tax non-gaap net non-gaap ep onward recast growth forma adjust ebitdaadjust ebitda onward recast margin robinson humphrey research estimatestick iqva
iqvia largest cro revenu oper countri employe
compani found headquart durham nc compani formerli quintil
merg im health combin entiti iqvia oper three segment commerci
solut data technolog drive real world evid use life sceinc client clinic
trial integr healthcar servic contract sale compris
respect sale iqvia first went public taken privat privat equiti
went public acquir im health
buy rate base view ebitda growth exceed revenu growth due
oper leverag cost synergi recognit expect manag reinforc oper
perform share repurchas expect contribut mid-teen ep growth
also think acquir im busi may benefit multipl expans mid-cap peer
technolog servic space given acquisit im
valuat risk
pt assign probabl low case price-to-earnings stock mid case
price-to-earnings stock high case price-to-earnings stock pt impli price-to-earnings
multipl ep estim ahead peer averag ntm multipl
justifi view given peer lead book perform anticip acceler revenu
growth one leader ep growth well view investor begin compar
mid/larg cap high visibl growth compani typic trade pe
low- mid-
risk rate price target
continu cancel late stage busi net book bill remain target
merger synergi fail materi custom attrit due im merger
sandi draper herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
